Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Single-center Retrospective Study with a Median Follow-up of 51.20 Months
Received 23 April 2020
Accepted for publication 4 August 2020
Published 28 September 2020 Volume 2020:12 Pages 439—446
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jan Colli
Roberto Jarimba,1 João Pedroso Lima,1 Miguel Eliseu,1 João Carvalho,1 Hugo Antunes,1,2 Edgar Tavares da Silva,1,2 Pedro Moreira,1 Arnaldo Figueiredo1,2
1Urology and Renal Transplantation Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Correspondence: Roberto Jarimba
Urology and Renal Transplantation Department, Centro Hospitalar e Universitário de Coimbra, Rua Professor Mota Pinto, Coimbra 3004-561, Portugal
Introduction: Prostate cancer is the most commonly diagnosed cancer in men. Radical prostatectomy is a potentially curative alternative for localized disease, although a significant percentage of these patients will suffer a biochemical recurrence with associated mortality. A wide spectrum of anticancer properties of statins has been demonstrated and the role of these drugs in prevention and treatment of other types of cancer is being increasingly studied.
Objective: The aim of this study was to investigate whether the use of statins is associated with reduced risk of biochemical recurrence among patients submitted to radical prostatectomy.
Patients and Methods: We retrospectively reviewed 875 patients submitted to radical prostatectomy between January 2009 and December 2018. Approximately 45.7% of the patients were on medication with statins at the time of surgery. We evaluated a possible association between statin use and biochemical recurrence and which patients would benefit the most with statin treatment.
Results: Overall, statins were associated with an approximately 40% reduction in risk of biochemical recurrence at a median follow-up time of 51.2 months (HR 0.599, p< 0.05). Patients with pT2c staging (HR 0.486, p=0.017) and ISUP ≥ 3 (HR 0.61, p=0.011) seem to have benefited more from statin use.
Conclusion: In this cohort, use of statins proved beneficial in reducing the risk of biochemical recurrence among patients submitted to radical prostatectomy. Prospective studies are required to confirm this result and to evaluate its safety profile in those patients.
Keywords: prevention, prostate cancer, radical prostatectomy, recurrence, statins
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]